Provincial Tax Advantage for Life Sciences Companies in British Columbia
Effective January 1, 2006, British Columbia's International Financial Activity Act has been expanded to allow a provincial tax refund for life Sciences Companies.
The sanofi-aventis biotech challenge competition for British Columbia will be held on Friday, April 28, 2006 in Townsquare A,B,C,D at the BCIT Burnaby Campus.
BC Biotech is proud to be hosting our 8th Annual BC Biotechnology Awards Ceremony May 4th to honour outstanding contributions made by members of British Columbia's biotechnology community. This event has evolved to become the premier evening of the year for biotech in BC, and we hope to have you all join us in this year's celebration.
This webcast will provide an overview of the medical device regulations of the Chinese State Food and Drug Administration (SFDA) as well as discuss the most recent regulatory issues. Topics covered include a number of new SFDA regulations, pitfalls to avoid, and strategies for a successful product registration.
Started in 1997, the Angel Forum-Vancouver introduces emerging companies to private equity investors, each spring and fall. It is the largest and oldest angel group in Canada with 100+ investors. Our sponsors include leading companies and industry associations in BC.
To help companies make the most out of their 20 minutes at Invest Northwest we invite you to rehearse your presentation in front of a live audience - a panel of VCs and industry experts - a few weeks prior to the conference to gain valuable feedback to help you prepare for Invest Northwest. Take advantage of this unique opportunity that will help polish your presentation!
VANCOUVER, Feb. 21 /CNW/ - AnorMED Inc. (TSX:AOM, AMEX:AOM) is pleased to announce that Michael Abrams, President and CEO, is the recipient of the Society of Chemical Industry's (SCI) 2006 Julia Levy Award recognizing successful innovation in Canada in the field of bio-medical science and engineering.
February 21, 2006 – Vancouver, BC - Ventures West, one of Canada’s largest private venture capital companies, is pleased to announce that Dr. Mohammad Azab has joined the firm as Entrepreneur in Residence. Dr. Azab, former Executive Vice President of Research and Development and Chief Medical Officer of QLT Inc., will be involved in identifying and evaluating investment opportunities in the biotech sector.
CANTEST announced today that it will contribute $250,000 towards research on the effects of chemical substances in the Environment on the health of Aboriginal people in Northern BC.
VANCOUVER, Feb. 15 /CNW/ - iCo Therapeutics Inc. announced today that it has selected Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) to manufacture and supply iCo 007. Under terms of the agreement, Isis will produce a sufficient quantity of iCo 007 for use in all Phase I and II studies.
VANCOUVER, Feb. 15 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP) corporate partner, Boston Scientific ("BSC") announced today that it has received reimbursement approval from the French government for its TAXUS(R) Liberté(TM) paclitaxel-eluting coronary stent system - the world's first next-generation drug-eluting stent system. The announcement was published yesterday in the official journal of the French government, "Journal Officiel de la République Française."
CONTACT
